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Abstract 
Background and aims 
Epidemiological evidence of the beneficial health effects of fish consumption is strong, but 
the evidence from intervention trials is less documented. Our aim was to evaluate the state of 
the evidence on the potential effects of fish consumption on vascular risk factors arising from 
intervention trials. 
Methods 
A systematic literature search was undertaken in OVID MEDLINE, Scopus, and EMBASE 
which were searched from inception to June 2017. A meta-analysis of intervention trials was 
performed to estimate the effect of fish consumption on vascular risk factors in adults 
(age >18 years). Primary outcomes included lipid biomarkers such as triglycerides, total 
cholesterol, HDL cholesterol and LDL cholesterol, and also novel biomarkers of vascular 
risk. Secondary outcomes were related to feasibility and acceptability aspects of these 
interventions. Random-effects models were used to determine the pooled effect sizes. 
Results 
14 trials, including a total of 1378 individuals, fulfilled the inclusion criteria for this study. 
Consuming oily fish was associated with significant reductions in plasma triglycerides (-0.11 
mmol/L; 95%CI -0.18 to -0.04; P= 0.002). While a significant increase in HDL-cholesterol 
was observed (0.06 mmol/L, 95%CI 0.02 to 0.11; P= 0.008). No significant effect could be 
observed on other vascular risk factors. 
Conclusion 
This study showed that there is evidence indicating that consuming oily fish lead to 
significant improvements in two important biomarkers of cardiovascular risk, such as 
triglycerides and HDL levels. These results strongly support the important role for oily fish as 
part of a healthy diet. 
Keywords: Fish Consumption, Cardiovascular Markers, Intervention, Systematic review, 
Meta-analysis 
  
Introduction 
Fish consumption is associated with cardiovascular disease (CVD) risk reduction in both 
observational and clinical intervention trials [1]. Fatty fish, such as salmon, tuna, herring, and 
mackerel are rich sources of omega-3 polyunsaturated fatty acids (n-3 PUFAs) which include 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which mediate the 
cardio-protective effects of fish [2]. It is commonly assumed that fish consumption is 
probably good for human health, especially because it provides high amounts of n-3 PUFAs, 
which lower triglycerides and, consequently, CVD [3]. In most previous experimental 
studies, which have investigated the effects of long-chain n-3 PUFAs on CVD risk, the doses 
of these fatty acids exceeded the amounts usually found in the diet. However, significant 
vascular benefits from modest fish consumption have been observed. In a prospective study, 
Yamagishi observed an inverse association between fish and n-3 PUFA consumption and the 
risks of mortality from heart failure (HF) and CVD [4]. The reduction in mortality associated 
with fish consumption is due to the positive effects on a number of cardiovascular risk 
factors. Fatty fish consumption can potentially modify both traditional and well-established 
markers, such as blood pressure, lipids and glucose; and novel markers such as adiponectin, 
leptin and inﬂammatory factors. Rajaram found that a diet rich in fish decreased serum 
triglyceride and increased HDL-cholesterol concentrations [5]. Consequently, adding oily 
fish to a daily diet decreased serum cholesterol and triglyceride concentrations, respectively, 
which affects CHD risk positively. Ramel observed that salmon consumption decreased 
diastolic blood pressure, similar to fish oil, and significantly more than lean fish. Among the 
most studied novel biomarkers are the inflammatory biomarkers and C-reactive protein 
(CRP) [6]. The use of novel biomarkers to increase standard risk algorithms has attracted 
increasing attention in recent years [7]. These biomarkers provide important prognostic 
information beyond that attainable with traditional cardiovascular risk factors in the setting of 
acute coronary syndrome [8]. Observational studies have consistently shown that higher 
plasma levels of CRP are linked with increased the risk of CHD and measurement of CRP 
has been suggested as a means of improving risk prediction [9]. Here, we systematically 
reviewed and meta-analysed available studies to evaluate the potential effects of fish 
consumption on vascular risk factors in randomised controlled trials (RCTs). 
  
Methods 
This systematic review was conducted according to The Cochrane [10] and the Centre for 
Reviews and Dissemination guidelines [11] and is reported according to PRISMA guidelines 
(Supplementary material: Table S1) [12]. The protocol has been registered with 
PROSPERO, the International Prospective Register of Systematic Reviews (Registration 
number CRD42016041288). 
The search strategy for the identification of the studies is summarized in Figure 1 and we 
identified the evidence published until June 2017. We used three electronic databases, OVID 
MEDLINE, Scopus, and EMBASE, and these were searched from inception. The search 
strategy included the following terms: fish OR “oil-rich fish” OR salmon OR sardine OR 
mackerel AND trial OR intervention AND cardiovascular markers. The systematic review 
was restricted to articles published in English. 
Two researchers (AA, JL) screened the titles and abstracts, selected the studies to be included 
in the review, and extracted the data. When screening the studies identified, the researchers 
decided whether the item was relevant or not, based on the title and abstract reading. If 
relevant, the referenced articles included in the item (review or meta-analysis) were passed to 
the list of potential articles to include in this review. When evaluating the clinical trials and 
RCTs, the researchers made an initial decision on the pertinence of the article and whether it 
should remain on the list based on the title and abstract reading, with the following inclusion 
and exclusion criteria: 
• Inclusion criteria: 
Clinical trials and RCTs, which directly assessed the effect of the intake of measured 
quantities of fish as a food on vascular risk factors, adult subjects >18 years of age, 
nutritional/dietary interventions and health-related outcomes. 
• Exclusion criteria:  
Articles written in languages other than English, subjects <18 years of age, non-
interventional studies, non-nutritional dietary interventions and non-physical capability 
interventions. 
Outcome measures 
The following lipid biomarkers were selected as primary outcome measures (Triglycerides, 
total-, HDL-, LDL- and VLDL-cholesterol) and systolic blood pressure (SBP), diastolic 
blood pressure (DBP), glucose, insulin and Homeostasis-Model-Assessment-Insulin 
Resistance (HOMA-IR), in addition to the inflammation markers, such as C-reactive protein 
(CRP), Interleukin-6 (IL-6) and Intercellular Adhesion Molecule (ICAM). Secondary 
outcomes were related to feasibility and acceptability aspects of these interventions. 
Data extraction 
The two reviewers extracted data independently and disagreements were resolved by 
consensus through discussion. The collected data included the author’s last name, year of 
publication, country where the study was conducted, mean or range of age, mean of BMI, 
sample size, duration of follow-up, proportion of men and women, dose and frequency of 
consumption, retention rate, control, feasibility and acceptability of these interventions and 
baseline and after intervention plasma lipids levels. In studies reporting consumption of fish 
and supplements such as fish oils, only the data related with fish was extracted.   
Statistical analysis 
The Review Manager (RevMan Version 5.3 for Windows Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2011) was used to pool and analyse results from the 
individual studies reviewed. Pooled results were reported as mean differences with 95% CI 
and with two-sided P-values. A random effects model accounting for inter-study variation 
was used, thereby minimizing potential bias due to methodological differences between 
studies. As suggested by Higgins and Green [10], excessive weightings from “double counts” 
originating from the control group were controlled by splitting the sample size of the shared 
group into approximately equal smaller groups for the comparisons; the means and standard 
deviations were left unchanged. The results are presented as forest plots. Statistical 
heterogeneity was evaluated using the I2 statistic, which is reported as a percentage; the 95% 
CI for I2 was calculated using Higgins and Thompson’s method [13]. Where I2 was >50%, 
the degree of heterogeneity was considered high. Evidence of publication bias was assessed 
by visual inspection of a funnel plot of effect size against the standard error (SE). Subgroup 
analysis was conducted according to sex, age, BMI, and health status of participants in the 
reviewed studies. Quality of studies was assessed using the Jadad score [14]  which ranges 
from 0–5 focusing on randomization, blinding and description of dropout or withdrawals. 
Because in the interventios studied it is difficult to blind participants to consuming fish, we 
considered the blinding of the outcome assessors as a quality criterion. 
  
Results 
The initial search identified 4,126 potentially relevant articles (2,390 from OVID MEDLINE, 
1,736 from Scopus and 1,500 from EMBASE). The articles became 3,459 after duplicates 
were removed. After an initial screening, based on titles and abstracts, 20 articles remained. 
After full-text assessment, 10 articles were excluded for various reasons and 7 additional 
articles were identified by other sources. Thus, the final set consisted of 17 articles reporting 
on 15 studies, which met our inclusion criteria and 13 studies provided data for the meta-
analysis, while four studies did not report the effects of fish consumption on vascular risk 
factors (Supplementary material Figure S13). 
Study inclusion and characteristics 
The search identified seventeen studies published between 1990 and 2014 that met our 
inclusion criteria and these studies were designed with parallel (n=9) and cross-over (n=5) 
protocols (Table 1). Four studies originated from the United Kingdom [15-18]; two from the 
USA [5, 19], Norway [20, 21], China [22, 23] and Australia [24, 25]; one study from Sweden 
[26], Denmark [27] and Spain [28]; and a collaborative study from Iceland/Spain/Ireland [29, 
30]. 
The pooled study populations included 1,378 participants who were, on average, followed-up 
for 9 weeks (follow-up range from 4 to 24 weeks). The sample size in the studies ranged from 
9 to 324. The mean ages of the samples in these studies ranged from 23 to 70 years. Seven 
studies included mixed sex samples, while six studies involved men only and two studies 
involved women only. Eight studies reported a mean BMI ≥25 kg/m2 at baseline thus 
including a significant proportion of overweight and obese participants, while mean BMI was 
≤25 in seven studies, and two studies did not report BMI (Supplementary material: Table 
S1). The frequencies for consuming fish ranged from once a week to daily consumption, and 
the portion size of oily fish (most commonly, salmon) consumed on a given day ranged from 
20 to 500 grams. All studies identified in this research required the fish to be consumed 
during the intervention. Seven studies involved healthy participants, three studies on 
overweight/obese, two studies involved patients with hyperlipidemia, one study on metabolic 
syndrome patients, one study on pregnant women and one study on CHD patients (Table 1). 
Various vascular risk factors (plasma lipids, inflammatory factors, and haemostasis) were 
evaluated in these studies. The overall percentage of subjects in RCTs who dropped out after 
randomization was small (7.5%). 
Study quality and publication bias 
The methodological quality and risk bias of the studies included in this review were assessed. 
The included studies were characterised as good quality on Jadad's Score, with most studies 
scoring ≥3 out of 5 total score. The average retention rate for the 14 RCTs was 92.5% for all 
studies and the reason for the dropouts were often not relative to the interventions 
themselves. Therefore, the majority of the included studies satisfied the criteria of the quality 
assessment tool. Blinding of participants and researchers delivering the intervention was 
generally not feasible in these interventions. In addition, these included studies provided an 
adequate description of methods and randomization procedures; thus, no studies were 
excluded from analysis based on quality assessment.  
Meta-analysis of vascular risk factors 
The meta-analysis of fourteen studies/subgroups, including 1,128 individuals (Figure 1), is 
shown in the forest plot displaying the 14 individual studies/subgroups, the weight allocated 
to each of these, and the overall effect size. The results show that interventions on oily fish 
consumption decrease the levels of triglycerides significantly (mean difference -0.11 mmol/L, 
95% confidence interval [CI]: -0.18 to -0.04, P= 0.002) in comparison with the control 
groups; the levels of heterogeneity are low: I2 = 0%. A funnel plot of the mean differences in 
triglyceride levels against standard error (SE) of all studies indicates lack of significant 
asymmetry suggesting an absence of publication bias (Figure S11). 
In addition, meta-analysis of twelve studies, including 1,104 individuals (Figure 2), shows 
that interventions on oily fish consumption increased the levels of HDL-cholesterol 
significantly (0.06 mmol/L, 95%CI: 0.02 to 0.11, P= 0.008) in comparison with the control 
groups; the levels of heterogeneity are low: I2 = 28%. A funnel plot of the mean differences 
in HDL levels against SEs of all studies indicates lack of significant asymmetry, suggesting 
the absence of publication bias (Figure S12).  
Subgroup analysis of these studies indicated that fish consumption was associated with 
reductions of triglycerides and HDL cholesterol, independent of sex, age, BMI or health 
status of participants (Table 2).    
Sensitivity analysis, investigating the influence of a single studies on the overall meta-
analysis estimate was carried out (supplementary material tables S2 and S3). Results 
showed robustness remaining significant after exclusion of single studies. Results were 
characterised by low level of heterogeneity.  
These studies did not show significant effects of fish consumption on other markers of 
vascular risk such as Total- or LDL-cholesterol, SBP, DBP, CRP, IL-6, ICAM, or insulin, 
glucose, or HOMA-IR (supplementary material Figures S1-S10).  
Studies not in meta-analysis 
In a 6-week intervention study [31], significant reductions of serum triglycerides (−0.50 
mmol/L), were reported in CHD patients consuming 700 g/week of salmon fed with a fish 
oil-based diet, thus having a greater content of n–3 fatty acids (30.2% weight) than in 
volunteers fed with salmon fillets containing intermediate (20.5% weight) and lower (11.7%) 
concentrations of n–3 PUFAs. In addition, another study reported that 500 g of mackerel per 
week for 4 weeks reduced platelet-monocyte aggregates by 35% in comparison with a control 
group receiving no dietary intervention [17].   
Discussion 
Statement of principal findings 
In the current meta-analysis of 14 published RCTs involving 1,378 adult participants, we 
found that consuming oily fish moderately (ranging from 20 g to 150 g per day) leads to a 
significant reduction in two important markers of cardiovascular risk, such as plasma 
triglycerides levels and an increase in HDL levels. We also found that fish consumption had 
no significant effect on total-, LDL-cholesterol, SBP, DBP, glucose, insulin, HOMA-IR, 
CRP, IL-6 and ICAM in both the short-to-medium term (4 to 12 months) and the longer term 
(>12 months). These findings support the beneficial effects of fish in reducing cardiovascular 
risk and highlight its important role as part of a healthy cardio-protective diet. 
 
Strengths and limitations 
To our knowledge, this report is the first systematic assessment through meta-analysis of the 
effectiveness of fish consumption on vascular risk factors among adult subjects >18 years of 
age within RCTs. We believe this review has several strengths. Firstly, this systematic review 
was conducted in adherence to standard guidelines and was based on three major electronic 
databases, namely, OVID MEDLINE, Scopus and EMBASE, which are considered to be the 
most relevant databases for this research topic. Secondly, there was a high retention rate 
(92.5%) among the selected studies for systematic review and meta-analysis (Table 1), which 
means that the majority of participants were satisfied with the fish-related diet they were 
given. In addition, this meta-analysis contains good quality studies reporting consistent 
results. Fourthly, the heterogeneity levels between the studies included in this meta-analysis 
were very low, in addition, the risk of publication bias was low, adding validity to the 
findings of this meta-analysis. Furthermore, the current meta-analysis only analysed data 
concerning fish consumption, thereby avoiding confounding factors, such as fish oil or other 
supplements as well as avoiding high heterogeneity. Sixthly, the amount of fish, which has 
been consumed in the studies, was provided to the participants to ensure that there was low 
variability in the serving size, as well as to reduce the dropout among the participants. Last, 
but not least, as most studies included in this analysis were performed in different populations 
(11 countries), the findings of this meta-analysis, therefore, are generalizable. 
Conversely, this meta-analysis has some limitations. First of all, it is worth noting that studies 
published in languages other than English were not included, due to the lack of translation 
resources. In addition, given that most studies provided the fish to be consumed during the 
trial, it remains to be assessed whether people is able to increase fish consumption after 
receiving advice to do so. Follow-up in the trials was too short to investigate cardiovascular 
morbidity or mortality. Therefore, outcomes were limited to surrogate markers, such as 
cardiovascular risk factors.  
 
Scientific analysis of findings 
Research into the effectiveness of fish consumption on vascular risk factors is still limited. As 
far as we are aware, there is no other systematic review regarding the relationship between 
fish consumption and vascular risk factors. The current study is an addition to the literature in 
this topic.  
The results of this systematic review suggest that the reduction of CVD mortality risk 
associated with the consumption of fish is likely to be related to the significant reductions in 
triglycerides and increases in HDL cholesterol. The epidemiological evidence suggests a 
strong association between fish consumption and lower risk of CVD [32, 33]. There is also 
some evidence suggesting that fish consumption is not related to myocardial infarction (MI) 
or stroke [34]. However, when pooling the epidemiological evidence together, several 
systematic reviews and meta-analyses of cohort studies indicate that fish consumption is 
associated with reductions in the risk for cardiovascular events [35-37].  
This systematic review also examined the effects of fish consumption on other CVD 
outcomes (the primary outcomes in this study, including inflammatory markers), and the 
results suggest there is no association between fish consumption and inflammatory markers. 
However, Zampelas et al [38] found that fish consumption was independently associated with 
lower inflammatory markers levels (on average, 33% lower CRP, 33% lower IL-6 and 21% 
lower TNF-alpha) among those healthy adults who consumed more than 300 g of fish per 
week. 
 
Implications for health 
The results of this review have important public health implications. The effects of fish 
consumption on vascular risk factors supports the view that eating fish has positive effects on 
well-established vascular risk factors, such as triglycerides and HDL-cholesterol. Intake of n-
3 fatty acids leads to a decrease in hepatic fatty acid output, as a result of increased fatty acid 
oxidation and decreased lipogenesis [39]. Some studies have evaluated the effect of feeding 
salmon with different types of diet in order to modify their omega-3 (n–3) PUFA content for 
human consumption showing significant reductions of serum triglycerides, VCAM, and IL-6 
[20]. These findings highlight the possibility of adapting salmon farming practices to provide 
food with enhanced cardio protective properties. A lower intake of salmon with increased n–3 
fatty acids concentrations might then be able to improve health outcomes. 
The potential benefit of fish consumption could be attributed to various types of nutrients 
(and their interactions), which are found abundantly in fish. For instance, fish is a good 
source of vitamins D and B complex, which have been linked to inverse cardiovascular risk 
[40]. However, most interventional evidence has focused on fish oils, and most controlled 
experimental studies on the impacts of fish consumption on cardiovascular risk factors are 
small and few in number compared with ﬁsh oils. Investigation of fish consumption and its 
impact on both traditional and novel risk factors in one comprehensive study is lacking. 
Animal studies suggest that fish consumption may increase levels of HDL-cholesterol, not 
only through the mechanism involving n-3 fatty acids, but also possibly through the effects 
exerted by fish proteins on lipid metabolism [41]. Fish protein is rich in essential amino acids 
and are easily digestible. Depending on the composition of the diet and the quantity of 
proteins, fish protein has reportedly promoted lipid secretion and slow absorption and 
synthesis of lipids [42]. 
 
Unanswered questions and future research 
This work has focused on markers of CVD, therefore it remains to be answered if fish 
consumption improves overall global health. This study did not identify studies focusing on 
people over the age of 70 years old nor less than 18 years old. Therefore, future research 
should evaluate whether the health effects of fish consumption on vascular risk factors are 
relevant to people in these age groups. With an increasing prevalence of CVD, there is a need 
for larger and long-term RCTs of the effectiveness of fish consumption on vascular risk 
factors. Further ongoing studies with sufficient sample size, standardized dosing, and 
adequate follow-up duration are required to clarify the role of fish and seafood for the 
prevention of CVD. 
 
Conclusion 
This systematic review and meta-analysis included all known RCTs of the effectiveness of 
fish consumption on vascular risk factors, including triglycerides, cholesterol, blood pressure 
and inflammatory factors, which were evaluated by reviewing the available published 
intervention trials. Evidence from this systematic review shows that consuming oily fish 
(ranging from 20 g to 150 g per day) leads to a moderately significant reduction in plasma 
triglycerides levels and an increase in HDL levels. These findings suggest that fish 
consumption directly influences important markers of cardiovascular risk in humans.  
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 Table 1. Characteristics of interventions included in a systematic review of fish consumption on vascular risk factors 
(Author/ 
year) country 
of origin 
Study 
design 
(Jadad 
score) 
Mean or 
Range 
Age 
(years) 
Mean 
BMI 
(kg/ m2) 
Participants 
healthy status 
Baseline 
sample 
size 
(sex % 
female) 
Intervention length (dose 
and frequency of 
consumption) 
Retention 
rate 
Control Feasibility and acceptability of these 
interventions 
[43] [25] 
Australia 
Randomised 
controlled 
trial (5) 
26 22.5 Healthy 
participants 
12 
(0%) 
6 weeks  
(200g/d of lean Australian 
fish) 
12 
(100%) 
No fish diet All participants showed a considerable 
interest in this study and they found no 
difficulty in eating their daily experimental 
meals.  
[19] USA Non-
randomised 
trial (2) 
30-65 
(range) 
- Healthy 
participants 
9 
(0%) 
40 days  
(Salmon diet)  
9 
(100%) 
No fish diet  No information was provided about 
feasibility and acceptability of the 
intervention. 
[44] Norway Randomised 
controlled 
trial (5) 
63 26-29 
 
(CHD) patients  60 
(13%) 
6 weeks  
(3 groups consuming 700 
g/wk of differently fed 
salmon)  
58 
(96.6%) 
No control One patient was excluded because of non-
adherence to the study protocol. Except for 
the excluded patients, all patients fulfilled 
the 6-week diet intervention according to 
the protocol. 
[15] UK Randomised 
controlled 
trial (5) 
35-65 
(range) 
30-32 Overweight and 
obese 
participants  
142 
 
(65%) 
24 weeks  
(2 portions of oily fish or 
white fish/wk) 
134 
(94%) 
No fish diet 8 subjects were excluded for different 
reasons, which included changes in 
health/medication, geographic location, 
work and inability to tolerate a cannula. 
[45] UK Non-
randomised 
trial (3) 
28 23 Healthy 
participants 
48 
(66%) 
4 weeks  
(125 g/day of salmon)   
48 
(100%) 
Follow-up 
period without 
fish  
Subjects reported being fond of fish and 
were willing to undertake a fish 
consumption period. However, 8 subjects 
did not undertake the on-fish period 
because they moved away after completing 
their academic grades. 
[17] UK Non-
randomised 
trial (1) 
24 24 Healthy 
participants 
28 
(0%) 
4 weeks  
(500 g of mackerel/wk) 
28 
(100%) 
No dietary 
intervention for 
a 4-week period 
No information was provided about 
feasibility and acceptability of the 
intervention. 
[46] [30] 
Iceland, Spain 
and Ireland 
Randomised 
controlled 
trial (5) 
31 30 Overweight and 
obese 
participants  
324 
(75%) 
8 weeks  
(150 g cod OR salmon 3 
times/wk OR 6 fish oil 
capsules/day) 
262 
(80%) 
 
275 
(84%) 
6 sunflower oil 
capsules per 
day, no seafood 
Some subjects did not complete the study 
for two reasons: the subjects were unable 
to follow the prescribed diet and lack of 
time to maintain the schedule of clinical 
visits. 
 [47] Sweden Cross-over 
Randomised 
controlled 
trial (3) 
48 28.3  Overweight 
participants 
40 
(0%) 
 6 weeks  
(150 g baked herring fillets 5 
times/wk) 
35 
(87.5%) 
150 g baked 
lean pork and 
chicken 5 
times/wk 
35 subjects completed the study. 4 of these 
35 subjects’ data was excluded in the TAG 
analyses due to having breakfast before 
sampling.  
[48] USA Randomised 
controlled 
trial (3) 
23-65 
(range) 
24.8 Healthy 
participants 
27 
(44%) 
4 weeks  
(113 g salmon twice/wk) 
25 
(92%) 
No fish diet 2 subjects dropped out because of time 
conflicts. 
[22] China Randomised 
controlled 
trial (3) 
50 26 Patients with 
hyperlipidemia 
100 
(0%) 
8 weeks 
(500 g of salmon/wk) 
92 
(92%) 
100 g pork, 
chicken or beef 
5 times/wk 
 OR 100 g 
hairtail or 
freshwater carp 
5 times/wk 
8 participants did not complete the 8-week 
study because of non-adherence to the 
study protocol or other personal reasons. 
[27] Denmark Randomised 
controlled 
trial (3) 
55 25 Healthy 
participants 
75 
(0%) 
8 weeks  
(150 g farmed trout/day) 
68 
(90.6%) 
150 g pure 
vegetable 
diet/day OR 150 
g chicken/day 
1 participant dropped out for personal 
reasons, 2 were dropped out due to illness 
during the study period, and 4 dropped out 
because they did not like the study meals. 
[49] UK Randomised 
controlled 
trial (3) 
29 - Pregnant 
women (<19 wk 
of gestation) 
123 
(100%) 
18 weeks 
(Two 150 g salmon 
portions/wk from 20 wk of 
gestation until delivery 
108 
(87.8%) 
Habitual diet 
(low in oily 
fish) 
15 women were unable to complete the 
study for different reasons (preterm 
delivery, withdrawal due to fatigue, a busy 
schedule, or some sort of injury). 
[21] Norway Randomised 
controlled 
trial (3) 
44 24 Healthy 
participants 
179 
(69%) 
7 weeks  
(34 g fish pate Or 500 ml 
fruit juice Or 3 capsules of 
fish oil/day) 
159 
(88.8%) 
No 
supplementation 
or food product  
Before the baseline visit, 9 subjects were 
lost, whereas 11 subjects dropped out 
during the study period. 4 subjects did not 
manage to consume the product and 2 had 
clinical symptoms and 5 were lost to 
follow-up. 
[23] China Randomised 
controlled 
trial (3) 
35–70 
(range) 
26 Patients with 
hypertriacylglyc
erolaemia  
131 
(100%) 
8 weeks  
(80 g salmon, herring or 
pompano 5 d/wk) 
126 
(96%) 
80 g meats 
(pork/chicken/ 
beef/lean fish) 
for 5 d/wk 
3 participants dropped out of the herring 
group for personal reasons. 1 participant 
dropped out of the salmon group because 
her husband was hospitalised after 
suffering a stroke, and 1 participant 
discontinued her participation in the 
control group because she moved away 
from the eating venue. 
 [28] Spain Randomised 
controlled 
trial (3) 
57 33 Metabolic 
syndrome 
patients 
273 
(48%) 
8 weeks  
(100 g/d of white fish) 
257 
(94%) 
 
No fish or 
seafood  
 
16 patients were lost to follow-up after the 
baseline evaluation and they desired not to 
go on with the protocol, although no 
adverse event was found in these patients. 
For the remaining participants, adherence 
was good and no violation of the pre-
established protocol was found. 
 
  
 Table 2. Subgroup analysis for effects of fish on triglycerides and HDL cholesterol  
Variable  Mean differences 
(95% CI) 
P  
(Z-test) 
Chi2  
(p-value) 
Heterogeneity 
I2 % 
Triglycerides     
Sex 
  
 
 Men only (n=4)  -0.15 (-0.31, 0.02) 0.09 3.19 (0.36) 6 
Mixed (n=5)  -0.11 (-0.21, -0.02) 0.02 0.34 (0.56) 0 
Women only (n=2)  -0.45 (-0.80, -0.10) 0.01 3.96 (0.41) 0 
Health status 
  
 
 Healthy subjects (n=10) 0.09 (-0.16, -0.01) 0.03 4.37 (0.89) 0 
Hyperlipidemia (n=2) -0.53 (-0.84, -0.21) 0.001 0.28 (0.59) 0 
BMI     
Normal weight (n=4) -0.09 (-0.20, 0.03) 0.15 3.44 (0.33) 15 
Overweight/Obese (n=10) -0.12 (-0.21, -0.03] 0.01 7.88 (0.34) 0 
Mean Age category     
≤ 30 years (n=3) -0.14 (-0.27, -0.02) 0.03 0.01 (0.93) 0 
>30 years (n=10) -0.10 (-0.19, -0.00] 0.04 11.44 (0.25) 14 
     
     
HDL-Cholesterol     
Sex     
Men only (n=4)  0.10 (0.04, 0.16) 0.001 1.44 (0.70) 0 
Mixed (n=5)  0.04 (-0.03, 0.11) 0.23 5.37 (0.37)  
Women only (n=2)  0.18 (0.06, 0.30) 0.004 0.02 (0.90) 0 
Health status     
Healthy subjects (n=10)  0.05 (0.00, 0.10) 0.05 6.43 (0.70) 0 
 Hyperlipidemia (n=2)  0.14 (0.07, 0.20) 0.0001 0.64 (0.42) 0 
BMI     
Normal weight (n=3) 0.07 (-0.03, 0.17) 0.14 2.87 (0.24) 30 
Overweight/Obese (n=10) 0.06 (0.00, 0.12) 0.04 8.09 (0.42) 34 
Mean Age category     
≤ 30 years (n=2) 0.16 (0.03, 0.29) 0.01 0.01 (0.93) 0 
>30 years (n=9) 0.05 (0.00, 0.10) 0.03 9.45 (0.40) 29 
 
  
 Supplementary material: 
Figure S1. Studies reporting total cholesterol level after consuming fish 
 
 
Figure S2. Studies reporting LDL-cholesterol level after consuming fish 
 
 
 
 
Figure S3. Studies reporting SBP level after consuming fish 
  
 
Figure S4. Studies reporting DBP level after consuming fish 
 
 
 
 
 
 
 
 
Figure S5. Studies reporting insulin level after consuming fish 
  
 
Figure S6. Studies reporting glucose level after consuming fish 
 
 
 
 
 
 
 
 
Figure S7. Studies reporting HOMA-IR level after consuming fish 
  
 
Figure S8. Studies reporting CRP level after consuming fish 
 
 
 
 
 
 
 
 
Figure S9. Studies reporting IL-6 level after consuming fish 
  
 
Figure S10. Studies reporting ICAM level after consuming fish 
 
 
 
 
  
 Figure S11. Funnel plot of Studies evaluating triglyceride levels after fish consumption. 
 
 
 
Figure S12. Funnel plot of Studies assessing HDL levels after fish consumption 
 
 
 
  
Figure S13. Flow diagram of selection of studies on fish consumption and vascular risk 
factors (PRISMA template) 
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 Table S1. PRISMA guidelines 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and implications 
of key findings; systematic review registration number.  
7 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  8-13 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
14 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
15 
Eligibility 
criteria  
6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
15 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
15 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
15 
Study 
selection  
9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
16 
Data 
collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
17 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
17 
Risk of bias 
in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
17 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  17 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
17-18 
Section/topic  # Checklist item  
Reported 
on page 
 #  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
17 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
 N/A 
RESULTS   
Study 
selection  
17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
20 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
20 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
26-28 
Results of 
individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
21-23 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
24-31 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  34 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
 N/A 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
35 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level 
(e.g., incomplete retrieval of identified research, reporting bias).  
35-36 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
41 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply 
of data); role of funders for the systematic review.  
 N/A 
N/A= Not applicable to this work 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred 
Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097.doi:10.1371/journal.pmed1000097 
For more information, visit: www.prisma-statement.org. 
  
 Table S2. Sensitivity analysis excluding single studies on the effects of fish on triglycerides  
Variable  Mean differences 
(95% CI) 
P  
(Z-test) 
Chi2  
(p-value) 
Heterogeneity 
I2 % 
Triglycerides     
All studies -0.11 [-0.18, -0.04] 0.002 12.1 (0.52) 0 
Minus study 1 -0.11 [-0.18, -0.04] 0.003 12.1 (0.44) 1 
Minus study 2 -0.11 [-0.18, -0.03] 0.006 12.1 (0.44) 1 
Minus study 3 -0.11 [-0.18, -0.03] 0.004 12.1 (0.44) 1 
Minus study 4 -0.13 [-0.20, -0.06] 0.0005 8.5 (0.75) 0 
Minus study 5 -0.10 [-0.18, -0.02] 0.02 11.7 (0.47) 0 
Minus study 6 -0.10 [-0.18, -0.03] 0.004 11.9 (0.45) 0 
Minus study 7 -0.11 [-0.18, -0.04] 0.003 11.96 (0.45) 0 
Minus study 8 -0.11 [-0.18, -0.04] 0.003 12.0 (0.45) 0 
Minus study 9 -0.11 [-0.18, -0.04] 0.002 11.42 (0.49) 0 
Minus study 10 -0.11 [-0.18, -0.03] 0.004 12.09 (0.44) 1 
Minus study 11 -0.10 [-0.17, -0.03] 0.005 9.02 (0.70) 0 
Minus study 12 -0.09 [-0.16, -0.02] 0.01 7.88 (0.79) 0 
Minus study 13 -0.11 [-0.18, -0.03] 0.005 12.06 (0.44) 1 
Minus study 14 -0.11 [-0.19, -0.04] 0.002 11.79 (0.46) 0 
 
  
 Table S3. Sensitivity analysis excluding single studies on the effects of fish on HDL-
cholesterol   
Variable  Mean differences 
(95% CI) 
P  
(Z-test) 
Chi2  
(p-value) 
Heterogeneity 
I2 % 
Triglycerides     
All studies 0.06 [0.02, 0.11] 0.008 16.69 (0.16) 28 
Minus study 1 0.06 [0.01, 0.11] 0.01 16.69 (0.12) 34 
Minus study 2 0.07 [0.03, 0.12] 0.002 13.99 (0.23) 21 
Minus study 3 0.06 [0.01, 0.11] 0.01 16.68 (0.12) 34 
Minus study 4 0.07 [0.02, 0.12] 0.007 16.04 (0.14) 31 
Minus study 5 0.05 [0.01, 0.10] 0.03 14.09 (0.23) 22 
Minus study 6 0.06 [0.01, 0.11] 0.02 15.86 (0.15) 31 
Minus study 7 0.07 [0.01, 0.12] 0.02 16.65 (0.12) 34 
Minus study 8 0.07 [0.02, 0.11] 0.01 16.59 (0.12) 34 
Minus study 9 0.06 [0.01, 0.11] 0.01 16.69 (0.12) 34 
Minus study 10 0.07 [0.01, 0.12] 0.01 16.61 (0.12) 34 
Minus study 11 0.05 [0.00, 0.10] 0.04 13.98 (0.23) 21 
Minus study 12 0.05 [0.01, 0.09] 0.02 12.72 (0.31) 13 
Minus study 13 0.08 [0.04, 0.13] <0.0001 10.98 (0.44) 0 
 
 
 
 
